Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Pegylated B-domain-deleted sequence-modified recombinant human factor VIII

EU orphan designation number: EU/3/10/847   
Active ingredient: Pegylated B-domain-deleted sequence-modified recombinant human factor VIII
Indication: Treatment of haemophilia A
Sponsor: Bayer Schering Pharma AG
D-13342 Berlin, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/02/2011 Centralised Orphan - Designation EMA/OD/128/10 (2011)1314 of 23/02/2011